title: [Angioendotheliomatosis proliferans systematizata].
abstract: Angioendotheliomatosis proliferans systematisata comprises two different entities; a malignant and benign (reactive) form. The more common malignant form with a fatal prognosis should be termed intravascular or angiotropic lymphoma and is a multifocal systemic disease, which affects especially the small and middle-sized blood vessels of the skin and central nervous system. Reactive angioendotheliomatosis is a benign disease, often associated with an infectious disease (predominantly with subacute bacterial endocarditis). We report a 38-year-old woman with a reactive angioendotheliomatosis and a 68-year-old man diagnosed as having the rare T-cell type of intravascular lymphoma.
authors.affiliation: Hautklinik Schwerin, Werderstrasse 30, 19049 Schwerin.
authors.forename: G
authors.initials: G
authors.lastname: Schley
authors.forename: D
authors.initials: D
authors.lastname: Kauffold
authors.forename: E
authors.initials: E
authors.lastname: Guse
authors.forename: S
authors.initials: S
authors.lastname: Slucka
authors.forename: M
authors.initials: M
authors.lastname: Jeschke
mesh_terms: D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000032:analysis; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000473:pathology; D009626:Terminology as Topic
chemical_list: D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D016898:Interferon-alpha; D002939:Ciprofloxacin; D011239:Prednisolone